Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.
Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.
Countries in the Asia Pacific (APAC) region have an opportunity, or a time-limited “gap,” to become leaders on the global biotechnology stage, panelists at the Bio Asia 2025 conference said in Singapore Sept. 9.
Results from the global phase III Harmoni trial presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) showed a statistically significant increase in progression-free survival after treatment with ivonescimab plus chemotherapy compared to chemotherapy alone, but failed to show a statistically significant benefit in overall survival (OS).
Summit Therapeutics Inc.’s presentation for bispecific antibody ivonescimab in non-small-cell lung cancer could draw some extra attention at next month’s World Conference on Lung Cancer meeting thanks to promising overall survival data from partner Akeso Pharmaceuticals Inc.’s China study of the PD-1/VEGF candidate.
Minghui Pharmaceutical Ltd. announced it is raising $131 million in a pre-IPO financing round Aug. 7. The funds will be used to advance its cancer and inflammatory disease pipeline, which include a PD-1/VEGF bispecific antibody, antibody-drug conjugates (ADCs) and a topical Janus kinase inhibitor.
Minghui Pharmaceutical Ltd. announced it is raising $131 million in a pre-IPO financing round Aug. 7. The funds will be used to advance its cancer and inflammatory disease pipeline, which include a PD-1/VEGF bispecific antibody, antibody-drug conjugates (ADCs) and a topical Janus kinase inhibitor.
T-cell engagers (TCEs) are a new class of immuno-oncology therapies that have proven effective for the treatment of both solid tumors and hematological malignancies. Among validated targets in this field, claudin 18.2 (CLDN18.2) is one of the most clinically established. Researchers from Astrazeneca plc and collaborators reported the preclinical evaluation of AZD-5863, a bispecific fully human monoclonal antibody targeting claudin CLDN18.2 and CD3.
Regeneron Pharmaceuticals Inc. disclosed within a positive second-quarter earnings report that it had received a complete response letter (CRL) two days earlier from the U.S. FDA for its bispecific antibody, odronextamab, for relapsed/refractory follicular lymphoma following two or more lines of systemic therapy.
Crossbow Therapeutics Inc. has nominated its second development candidate, CBX-663, a T-cell engager for the treatment of a broad range of solid tumors and hematologic malignancies.
RSS
